Ningbo MedicalSystem Biotechnology Co Ltd Total Liabilities
Ningbo MedicalSystem Biotechnology Co Ltd total liabilities. Based on the latest financial reports, Ningbo MedicalSystem Biotechnology Co Ltd (300439) has total liabilities worth CN¥706.76 Million CNY (≈ $103.42 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 300439 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ningbo MedicalSystem Biotechnology Co Ltd (2011–2024)
Total liabilities of Ningbo MedicalSystem Biotechnology Co Ltd from 2011 to 2024. This chart illustrates how Ningbo MedicalSystem Biotechnology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Ningbo MedicalSystem Biotechnology Co Lt long-term investment intensity to see how much of total assets are deployed in long-term investments.
Ningbo MedicalSystem Biotechnology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Ningbo MedicalSystem Biotechnology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Baotou Huazi Industry Co Ltd
SHG:600191
|
China | CN¥563.98 Million |
|
Beijing Bayi Space LCD Technology Co Ltd
SHG:688181
|
China | CN¥1.10 Billion |
|
Pepper Money Ltd
AU:PPM
|
Australia | AU$17.53 Billion |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-C
|
Sweden | Skr3.89 Trillion |
|
Amos Luzon Development and Energy Group Ltd
TA:LUZN
|
Israel | ILA3.72 Billion |
|
Qingdao Liqun Department Store Group Co Ltd
SHG:601366
|
China | CN¥10.13 Billion |
|
Hengyuan Refining Company Bhd
KLSE:4324
|
Malaysia | RM3.59 Billion |
|
Matas A/S
CO:MATAS
|
Denmark | Dkr5.90 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Ningbo MedicalSystem Biotechnology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Ningbo MedicalSystem Biotechnology Co Lt's balance sheet.
Liquidity & Leverage Metrics
Ningbo MedicalSystem Biotechnology Co Ltd Total Liabilities Ratios Explained
Ningbo MedicalSystem Biotechnology Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ningbo MedicalSystem Biotechnology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ningbo MedicalSystem Biotechnology Co Ltd (2011–2024)
The table below shows the annual total liabilities of Ningbo MedicalSystem Biotechnology Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥771.65 Million ≈ $112.92 Million |
-1.39% |
| 2023-12-31 | CN¥782.49 Million ≈ $114.50 Million |
-26.47% |
| 2022-12-31 | CN¥1.06 Billion ≈ $155.73 Million |
-11.49% |
| 2021-12-31 | CN¥1.20 Billion ≈ $175.96 Million |
-23.27% |
| 2020-12-31 | CN¥1.57 Billion ≈ $229.33 Million |
-33.38% |
| 2019-12-31 | CN¥2.35 Billion ≈ $344.25 Million |
+1.09% |
| 2018-12-31 | CN¥2.33 Billion ≈ $340.54 Million |
+16.84% |
| 2017-12-31 | CN¥1.99 Billion ≈ $291.46 Million |
+25.27% |
| 2016-12-31 | CN¥1.59 Billion ≈ $232.66 Million |
+897.74% |
| 2015-12-31 | CN¥159.36 Million ≈ $23.32 Million |
-22.69% |
| 2014-12-31 | CN¥206.12 Million ≈ $30.16 Million |
+26.77% |
| 2013-12-31 | CN¥162.59 Million ≈ $23.79 Million |
+26.38% |
| 2012-12-31 | CN¥128.66 Million ≈ $18.83 Million |
+88.31% |
| 2011-12-31 | CN¥68.32 Million ≈ $10.00 Million |
-- |
About Ningbo MedicalSystem Biotechnology Co Ltd
Medicalsystem Biotechnology Co., Ltd. engages in the research, development, production, and sales of in vitro diagnostic products in China. It is also involved in the provision of Three-party medical diagnosis services. The company offers automated chemistry analyzers; and automated chemiluminescence immunoassay analyzer; hematology analyzers and reagents; total laboratory automation system; mass… Read more